NYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free GKOS Stock Alerts $109.83 +2.21 (+2.05%) (As of 03:08 PM ET) Add Compare Share Share Today's Range$107.83▼$110.0050-Day Range$84.31▼$107.9352-Week Range$54.38▼$110.73Volume131,768 shsAverage Volume638,164 shsMarket Capitalization$5.53 billionP/E RatioN/ADividend YieldN/APrice Target$108.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Glaukos alerts: Email Address Glaukos MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside1.1% Downside$108.64 Price TargetShort InterestBearish6.97% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.63Based on 22 Articles This WeekInsider TradingSelling Shares$21.77 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.20) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector216th out of 915 stocksSurgical & Medical Instruments Industry29th out of 96 stocks 2.4 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGlaukos has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Glaukos' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.97% of the outstanding shares of Glaukos have been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Glaukos has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 3.7 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Glaukos this week, compared to 5 articles on an average week.Search Interest3 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,767,497.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Glaukos' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.20) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -38.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -38.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 11.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Glaukos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Glaukos Stock (NYSE:GKOS)Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Read More GKOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Stock News HeadlinesMay 9, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 105 SharesMay 7, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 442 SharesMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."April 11, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) COO Sells $6,008,206.47 in StockApril 10, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,372 SharesMay 8, 2024 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$113May 8, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Rating Increased to Buy at Jefferies Financial GroupMay 7, 2024 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 2,059 Shares of StockMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."May 6, 2024 | msn.comJefferies Upgrades Glaukos (GKOS)May 6, 2024 | msn.comGlaukos rises on upgrade to Buy at JefferiesMay 6, 2024 | markets.businessinsider.comBuy Rating on Glaukos with Strong Growth Prospects for iDose and MIGS Market ShareMay 6, 2024 | americanbankingnews.comNeedham & Company LLC Boosts Glaukos (NYSE:GKOS) Price Target to $113.00May 6, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Price Target Increased to $112.00 by Analysts at BTIG ResearchMay 3, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Sets New 52-Week High Following Analyst UpgradeMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising iDose ProspectsMay 2, 2024 | msn.comGlaukos Corporation (NYSE:GKOS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comGlaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...May 2, 2024 | gurufocus.comQ1 2024 Glaukos Corp Earnings Call TranscriptMay 2, 2024 | investing.comGlaukos Corp (GKOS) Earnings Dates & ReportsMay 2, 2024 | msn.comGKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comGlaukos Announces First Quarter 2024 Financial ResultsMay 1, 2024 | finance.yahoo.comGlaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue ExpectationsApril 30, 2024 | markets.businessinsider.comHere's what to expect from Glaukos's earnings reportApril 16, 2024 | businesswire.comGlaukos Announces the Release of its 2023 Sustainability ReportApril 13, 2024 | ca.news.yahoo.comSpeaker Johnson welcomes Japanese PM Kishida and his wife to the CapitolApril 11, 2024 | finance.yahoo.comIs Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)?See More Headlines Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/10/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees907Year FoundedN/APrice Target and Rating Average Stock Price Target$108.64 High Stock Price Target$125.00 Low Stock Price Target$65.00 Potential Upside/Downside+0.9%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,660,000.00 Net Margins-43.15% Pretax Margin-42.88% Return on Equity-24.69% Return on Assets-12.27% Debt Debt-to-Equity Ratio0.78 Current Ratio5.38 Quick Ratio4.68 Sales & Book Value Annual Sales$326.43 million Price / Sales16.61 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book11.38Miscellaneous Outstanding Shares50,368,000Free Float46,976,000Market Cap$5.42 billion OptionableOptionable Beta1.08 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Thomas William Burns (Age 63)Chairman & CEO Comp: $774.9kMr. Joseph E. Gilliam (Age 48)President & COO Comp: $1.18MMr. Alex R. Thurman (Age 54)Senior VP & CFO Comp: $621.24kDr. Tomas Navratil Ph.D. (Age 47)Chief Development Officer Comp: $866.18kDr. Mory Gharib Ph.D.Co-FounderMr. Christopher William LewisVice President of Investor Relations & Corporate AffairsMs. Diana A. SchererVP of Compliance & Deputy General CounselMs. Michele M. AllegrettoSenior Vice President of Human ResourcesMr. Chris M. Calcaterra (Age 64)Executive Vice President of Global Commercial Operations Comp: $198.66kMs. Jane E. Rady (Age 76)Senior Vice President of Corporate Strategy & Business Development More ExecutivesKey CompetitorsHaemoneticsNYSE:HAEMerit Medical SystemsNASDAQ:MMSIGlobus MedicalNYSE:GMEDAxonicsNASDAQ:AXNXInspire Medical SystemsNYSE:INSPView All CompetitorsInsiders & InstitutionsBlair William & Co. ILBought 2,863 shares on 5/9/2024Ownership: 0.099%State Board of Administration of Florida Retirement SystemBought 1,360 shares on 5/9/2024Ownership: 0.029%ProShare Advisors LLCBought 637 shares on 5/8/2024Ownership: 0.019%US Bancorp DESold 1,043 shares on 5/8/2024Ownership: 0.011%Inspire Investing LLCSold 1,084 shares on 5/8/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions GKOS Stock Analysis - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price target for 2024? 11 analysts have issued 12-month price targets for Glaukos' shares. Their GKOS share price targets range from $65.00 to $125.00. On average, they expect the company's stock price to reach $108.64 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2024? Glaukos' stock was trading at $79.49 at the beginning of the year. Since then, GKOS shares have increased by 38.2% and is now trading at $109.84. View the best growth stocks for 2024 here. Are investors shorting Glaukos? Glaukos saw a increase in short interest in April. As of April 30th, there was short interest totaling 3,510,000 shares, an increase of 6.7% from the April 15th total of 3,290,000 shares. Based on an average trading volume of 517,300 shares, the days-to-cover ratio is presently 6.8 days. View Glaukos' Short Interest. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GKOS earnings forecast. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) released its quarterly earnings results on Wednesday, May, 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.12. The medical instruments supplier had revenue of $85.60 million for the quarter, compared to analysts' expectations of $79.60 million. Glaukos had a negative trailing twelve-month return on equity of 24.69% and a negative net margin of 43.15%. The firm's revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.59) EPS. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Momentum ETF (XSMO), Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Principal Healthcare Innovators ETF (BTEC) and iShares S&P Small-Cap 600 Growth ETF (IJT). What guidance has Glaukos issued on next quarter's earnings? Glaukos updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $357.0 million-$365.0 million, compared to the consensus revenue estimate of $356.7 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? Glaukos (GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Glaukos' stock is owned by a number of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (1.06%), Allspring Global Investments Holdings LLC (0.34%), Allspring Global Investments Holdings LLC (0.33%), Peregrine Capital Management LLC (0.20%), Swiss National Bank (0.18%) and Sei Investments Co. (0.14%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:GKOS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.